{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T15:10:19Z","timestamp":1782141019416,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"S5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Innsbruck and Medical University of Innsbruck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Immunglobulin\u00a0A Nephropathie (IgAN) ist die h\u00e4ufigste Glomerulonephritis weltweit und f\u00fchrt bei ungef\u00e4hr einem Drittel der PatientInnen innerhalb von 10\u00a0bis 20\u00a0Jahren zur terminalen Nierenerkrankung. Die Pathogenese der IgAN ist nicht eindeutig gekl\u00e4rt. Vermutlich kommt es durch eine Dysregulation des mukosalen Immunsystems zu einer Untergalaktosylierung der IgA-Molek\u00fcle, Bildung von IgG Auto-Antik\u00f6rpern und zur Zirkulation von IgG-IgA-Immunkomplexen, welche sich im Mesangium ablagern und schlie\u00dflich zur Glomerulonephritis f\u00fchren. Eine IgAN kann gelegentlich durch eine andere Erkrankung ausgel\u00f6st werden, deswegen sollten diese sekund\u00e4ren Ursachen einer IgAN identifiziert bzw. ausgeschlossen werden (chronisch entz\u00fcndliche Darmerkrankungen, Infektionen, Tumore, rheumatische Erkrankungen). Charakteristische Befunde einer IgAN im variablen Ausma\u00df sind ein nephritisches Harnsediment (dysmorphe Erythrozyten, Akanthozyten, Erythrozytenzylinder), Proteinurie, eine Einschr\u00e4nkung der Nierenfunktion, eine arterielle Hypertonie, oder auch eine intermittierende schmerzlose Makroh\u00e4maturie, vor allem bei Infekten des oberen Respirationstraktes. Die Diagnose einer IgAN kann jedoch ausschlie\u00dflich durch eine Nierenbiopsie gestellt werden. Dabei sollte eine histologische Klassifizierung (MEST\u2011C score) durchgef\u00fchrt werden, um die Prognose absch\u00e4tzen zu k\u00f6nnen. Die wichtigste therapeutische Ma\u00dfnahme besteht in einer Optimierung der supportiven Therapie, das beinhaltet u.\u202fa. eine konsequente Kontrolle des Blutdrucks, eine Hemmung des RAS, und die Gabe eines SGLT2-Hemmers. Eine systemische immunsuppressive Therapie mit Kortikosteroiden wird kontroversiell diskutiert, sollte restriktiv gehandhabt und nur nach individueller Nutzen-Risiko-Abw\u00e4gung unter bestimmten Bedingungen, die f\u00fcr eine progressive IgAN sprechen, verabreicht werden. Neue vielversprechende Therapeutika sind enterales Budesonid oder der duale Angiotensin-II-Rezeptor- und Endothelin-Rezeptor-Antagonist Sparsentan. Eine rapid-progressive IgAN sollte mit Kortikosteroiden und Cyclophosphamid \u00e4hnlich einer ANCA-assoziierten Vaskulitis behandelt werden.<\/jats:p>","DOI":"10.1007\/s00508-023-02257-6","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:01:56Z","timestamp":1695214916000},"page":"621-627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnostik und Therapie IgA Nephropathie\u00a0\u2013 2023","Diagnosis and Treatment of IgA Nephropathy\u20142023"],"prefix":"10.1007","volume":"135","author":[{"given":"Judith","family":"Schimpf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Zitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Eller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus D.","family":"S\u00e4emann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Lhotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"issue":"2","key":"2257_CR1","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1093\/ndt\/gfq665","volume":"26","author":"A McGrogan","year":"2011","unstructured":"McGrogan\u00a0A, Franssen\u00a0CF, de Vries\u00a0CS. The incidence of primary glomerulonephritis worldwide: a\u00a0systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2257_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ng.787","volume":"43","author":"AG Gharavi","year":"2011","unstructured":"Gharavi\u00a0AG, Kiryluk\u00a0K, Choi\u00a0M, Li\u00a0Y, Hou\u00a0P, Xie\u00a0J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43(4):321\u20137.","journal-title":"Nat Genet"},{"issue":"3","key":"2257_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut\u00a0P, Avila-Casado\u00a0C, Reich\u00a0HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2257_CR4","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","volume":"179","author":"SJ Barbour","year":"2019","unstructured":"Barbour\u00a0SJ, Coppo\u00a0R, Zhang\u00a0H, Liu\u00a0ZH, Suzuki\u00a0Y, Matsuzaki\u00a0K, et al. Evaluating a\u00a0new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942\u201352.","journal-title":"JAMA Intern Med"},{"issue":"4S","key":"2257_CR5","first-page":"S1","volume":"100","author":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1\u2013S276.","journal-title":"Kidney Int"},{"issue":"1","key":"2257_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler\u00a0DC, Toto\u00a0RD, Stefansson\u00a0BV, Jongs\u00a0N, Chertow\u00a0GM, Greene\u00a0T, et al. A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324.","journal-title":"Kidney Int"},{"issue":"9","key":"2257_CR7","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1681\/ASN.2014070697","volume":"26","author":"V Tesar","year":"2015","unstructured":"Tesar\u00a0V, Troyanov\u00a0S, Bellur\u00a0S, Verhave\u00a0JC, Cook\u00a0HT, Feehally\u00a0J, et\u00a0al. Corticosteroids in IgA nephropathy: a\u00a0retrospective analysis from the VALIGA study. J\u00a0Am Soc Nephrol. 2015;26(9):2248\u201358.","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"2257_CR8","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen\u00a0T, Eitner\u00a0F, Fitzner\u00a0C, Sommerer\u00a0C, Zeier\u00a0M, Otte\u00a0B, et\u00a0al. Intensive supportive care plus immunosuppression in IgA nephropathy. N\u00a0Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"10","key":"2257_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1681\/ASN.2010010076","volume":"21","author":"J Feehally","year":"2010","unstructured":"Feehally\u00a0J, Farrall\u00a0M, Boland\u00a0A, Gale\u00a0DP, Gut\u00a0I, Heath\u00a0S, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J\u00a0Am Soc Nephrol. 2010;21(10):1791\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2257_CR10","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI74475","volume":"124","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk\u00a0K, Novak\u00a0J. The genetics and immunobiology of IgA nephropathy. J\u00a0Clin Invest. 2014;124(6):2325\u201332.","journal-title":"J Clin Invest"},{"issue":"1","key":"2257_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1172\/JCI5535","volume":"104","author":"M Tomana","year":"1999","unstructured":"Tomana\u00a0M, Novak\u00a0J, Julian\u00a0BA, Matousovic\u00a0K, Konecny\u00a0K, Mestecky\u00a0J. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J\u00a0Clin Invest. 1999;104(1):73\u201381.","journal-title":"J Clin Invest"},{"issue":"10","key":"2257_CR12","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki\u00a0H, Kiryluk\u00a0K, Novak\u00a0J, Moldoveanu\u00a0Z, Herr\u00a0AB, Renfrow\u00a0MB, et\u00a0al. The pathophysiology of IgA nephropathy. J\u00a0Am Soc Nephrol. 2011;22(10):1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2257_CR13","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2021.04.017","volume":"78","author":"J Savige","year":"2021","unstructured":"Savige\u00a0J, Harraka\u00a0P. Pathogenic variants in the genes affected in alport syndrome (COL4A3-COL4A5) and their association with other kidney conditions: a\u00a0review. Am J Kidney Dis. 2021;78(6):857\u201364.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2257_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi\u00a0H, Barratt\u00a0J, Cattran\u00a0DC, Cook\u00a0HT, Coppo\u00a0R, Haas\u00a0M, et\u00a0al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014\u201321.","journal-title":"Kidney Int"},{"issue":"4","key":"2257_CR15","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues\u00a0JC, Haas\u00a0M, Reich\u00a0HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2257_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2215\/CJN.11951113","volume":"9","author":"LC Herlitz","year":"2014","unstructured":"Herlitz\u00a0LC, Bomback\u00a0AS, Stokes\u00a0MB, Radhakrishnan\u00a0J, D\u2019Agati\u00a0VD, Markowitz\u00a0GS. IgA nephropathy with minimal change disease. Clin J Am Soc Nephrol. 2014;9(6):1033\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2257_CR17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","volume":"110","author":"CC Szeto","year":"2001","unstructured":"Szeto\u00a0CC, Lai\u00a0FM, To\u00a0KF, Wong\u00a0TY, Chow\u00a0KM, Choi\u00a0PC, et\u00a0al. The natural history of immunoglobulin a\u00a0nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110(6):434\u20137.","journal-title":"Am J Med"},{"issue":"11","key":"2257_CR18","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/ndt\/gfx242","volume":"32","author":"T Knoop","year":"2017","unstructured":"Knoop\u00a0T, Vikse\u00a0BE, Mwakimonga\u00a0A, Leh\u00a0S, Bjorneklett\u00a0R. Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant. 2017;32(11):1841\u201350.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2257_CR19","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen\u00a0T, Wied\u00a0S, Fitzner\u00a0C, Eitner\u00a0F, Sommerer\u00a0C, Zeier\u00a0M, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044\u201352.","journal-title":"Kidney Int"},{"key":"2257_CR20","doi-asserted-by":"crossref","unstructured":"Group E\u2011KC, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022;388(2):117\u201327.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"1","key":"2257_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ekir.2021.11.001","volume":"7","author":"S Troyanov","year":"2022","unstructured":"Troyanov\u00a0S, Hladunewich\u00a0MA, Reich\u00a0HN. How should pathology findings influence treatment in IgA nephropathy? Kidney Int Rep. 2022;7(1):3\u20135.","journal-title":"Kidney Int Rep"},{"issue":"19","key":"2257_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327(19):1888\u201398.","journal-title":"JAMA"},{"issue":"10084","key":"2257_CR23","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstrom","year":"2017","unstructured":"Fellstrom\u00a0BC, Barratt\u00a0J, Cook\u00a0H, Coppo\u00a0R, Feehally\u00a0J, de Fijter\u00a0JW, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a\u00a0double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389(10084):2117\u201327.","journal-title":"Lancet"},{"issue":"2","key":"2257_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2022","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2022;103(2):391\u2013402.","journal-title":"Kidney Int."},{"issue":"1","key":"2257_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","volume":"74","author":"LJ Liu","year":"2019","unstructured":"Liu\u00a0LJ, Yang\u00a0YZ, Shi\u00a0SF, Bao\u00a0YF, Yang\u00a0C, Zhu\u00a0SN, et\u00a0al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a\u00a0randomized controlled trial. Am J Kidney Dis. 2019;74(1):15\u201322.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2257_CR26","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2215\/CJN.00910121","volume":"16","author":"A Uffing","year":"2021","unstructured":"Uffing\u00a0A, Perez-Saez\u00a0MJ, Jouve\u00a0T, Bugnazet\u00a0M, Malvezzi\u00a0P, Muhsin\u00a0SA, et al. Recurrence of IgA nephropathy after kidney transplantation in adults. Clin J Am Soc Nephrol. 2021;16(8):1247\u201355.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2257_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000446354","volume":"44","author":"Y Liu","year":"2016","unstructured":"Liu\u00a0Y, Ma\u00a0X, Zheng\u00a0J, Liu\u00a0X, Yan\u00a0T. A\u00a0systematic review and meta-analysis of kidney and pregnancy outcomes in IgA nephropathy. Am J Nephrol. 2016;44(3):187\u201393.","journal-title":"Am J Nephrol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-023-02257-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-023-02257-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T13:17:40Z","timestamp":1695215860000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-023-02257-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":27,"journal-issue":{"issue":"S5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2257"],"URL":"https:\/\/doi.org\/10.1007\/s00508-023-02257-6","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"24 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Schimpf, A.\u00a0Kronbichler, M.\u00a0Windpessl, E.\u00a0Zitt, K.\u00a0Eller, M.D.\u00a0S\u00e4emann, K.\u00a0Lhotta und M.\u00a0Rudnicki geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}